Traws Pharma Inc
$ 0.52
-4.11%
23 Jul - close price
- Market Cap 8,258,300 USD
- Current Price $ 0.52
- High / Low $ 0.54 / 0.52
- Stock P/E N/A
- Book Value -0.52
- EPS -1.67
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.90 %
- ROE -56.39 %
- 52 Week High 3.27
- 52 Week Low 0.52
About
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. The company is headquartered in Newtown, Pennsylvania.
Analyst Target Price
$1.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-15 | 2025-12-31 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-14 | 2024-08-15 | 2024-04-01 | 2024-03-14 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -0.52 | -0.5544 | -0.34 | -0.16 | 2.09 | 26.6 | -8.81 | -121.75 | -5 | -0.19 | -5.75 | -5 |
| Estimated EPS | -0.56 | -0.54 | -9.16 | -8.75 | -0.265 | -0.25 | -6.25 | -6.25 | -6.33 | -0.25 | -7.25 | -7.81 |
| Surprise | 0.04 | -0.0144 | 8.82 | 8.59 | 2.355 | 26.85 | -2.56 | -115.5 | 1.33 | 0.06 | 1.5 | 2.81 |
| Surprise Percentage | 7.1429% | -2.6667% | 96.2882% | 98.1714% | 888.6792% | 10740% | -40.96% | -1848% | 21.0111% | 24% | 20.6897% | 35.9795% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TRAW
2026-07-18 21:40:34
Traws Pharma (TRAW) has filed a registration summary outlining its business model as a clinical-stage biopharmaceutical company focused on antiviral and oncology therapies. The company faces financial challenges, including recurring losses and liquidity concerns, but is seeking to fund its clinical and preclinical programs through registered securities. Recent events include an AGM, Q4 2024 and Q1 2026 results, and several proxy filings related to governance and financing.
2026-07-16 17:46:00
This article reports on a Form 4 filing for Traws Pharma Inc. on July 16, 2026. The article itself is very brief, serving primarily as a notification rather than detailed financial news. It indicates the stock symbol TRAW and its performance on that date.
2026-07-16 17:10:15
Traws Pharma, Inc. (TRAW) has granted 97,000 stock options to its Chief Science Officer of Virology, Charles David Pauza. The options, priced at $0.68 per share, are part of a compensation award and will vest 100% on July 9, 2027, with an expiration date of July 9, 2036. This transaction strengthens Pauza's direct holdings in the company, aligning his incentives with Traws Pharma's performance.
2026-07-16 01:41:38
Traws Pharma (TRAW) has granted 14,150 stock options to its director Werner Cautreels. These options, awarded on July 9, 2026, have an exercise price of $0.68 per share, will vest 100% after one year, and are set to expire on July 9, 2036. This transaction was reported on an SEC Form 4 filing, detailing the grant under the company's 2021 Incentive Compensation Plan.
2026-07-16 00:10:15
Traws Pharma (TRAW) has granted its Chief Financial Officer, Parker Charles Nolan, 90,000 stock options with an exercise price of $0.68 per share. These options will vest completely on July 9, 2027, which is the first anniversary of the grant date, and will expire on July 9, 2036. The award was made under the company's 2021 Incentive Compensation Plan, bringing Nolan's total direct holdings to 90,000 stock options.
2026-07-15 21:38:00
This article from Investing.com reports on a Form 4 filing for Traws Pharma Inc on July 15th, noting that the company's stock symbol is TRAW and its price increased by 1.47%. The content primarily consists of market data, news headlines, and navigational links, typical of a financial news platform.
